.jpg)
3 hours ago
1
Article content
“In addition to these strong Q1 financial results, I am pleased to announce the election to the Board of Directors today of Mr. Prakash Gowd, who replaces Mr. Larry Andrews upon his retirement from the Board. Mr. Gowd is an accomplished business leader with extensive healthcare industry experience and expertise. He will be an asset to the Board through the next phase of BioSyent’s continued growth. I would like to thank Mr. Andrews for his 7 years of service on the Board and his commitment and contributions to BioSyent’s continued success during his tenure.”
Article content
The CEO’s presentation on the Q1 2025 Results is available at the following link: www.biosyent.com/investors/
Article content
The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management’s Discussion and Analysis for the three months ended March 31, 2025 and 2024 will be posted on www.sedarplus.ca on May 15, 2025.
Article content
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
Article content
About BioSyent Inc.
Article content
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
Article content
Article content
As of the date of this press release, the Company has 11,254,638 common shares outstanding.
Article content
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Comprehensive Income | ||||||
| In Canadian Dollars | Q1 2025 | Q1 2024 | % Change | |||
| Net Revenues | 10,978,960 | 7,733,636 | 42 | % | ||
| Cost of Goods Sold | 2,641,768 | 1,589,762 | 66 | % | ||
| Gross Profit | 8,337,192 | 6,143,874 | 36 | % | ||
| Operating Expenses and Finance Income/Costs | 5,180,821 | 3,737,443 | 39 | % | ||
| Net Income Before Tax | 3,156,371 | 2,406,431 | 31 | % | ||
| Tax (including Deferred Tax) | 836,438 | 637,704 | 31 | % | ||
| Net Income After Taxes | 2,319,933 | 1,768,727 | 31 | % | ||
| Net Income After Taxes % to Net Revenues | 21 | % | 23 | % | ||
| EBITDA1 | 3,201,647 | 2,204,193 | 45 | % | ||
| EBITDA1 % to Net Revenues | 29 | % | 29 | % | ||
Article content
- EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.
Article content
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Financial Position | ||||||
| AS AT | March 31, 2025 | December 31, 2024 | % Change | |||
| ASSETS | ||||||
| Cash, cash equivalents and short-term investments | $ | 17,401,557 | $ | 15,940,971 | 9 | % |
| Trade and other receivables | 5,426,657 | 2,906,829 | 87 | % | ||
| Inventory | 5,277,242 | 5,328,086 | -1 | % | ||
| Prepaid expenses and deposits | 484,654 | 201,971 | 140 | % | ||
| Derivative asset | – | 5,790 | – | |||
| Loans receivable – current | 52,004 | 87,433 | -41 | % | ||
| CURRENT ASSETS | 28,642,114 | 24,471,080 | 17 | % | ||
| Long term investments | 7,497,025 | 10,103,571 | -26 | % | ||
| Loans receivable – non current | 123,170 | 141,140 | -13 | % | ||
| Deferred tax asset | 380,206 | 401,166 | -5 | % | ||
| Property and equipment | 1,153,985 | 1,200,992 | -4 | % | ||
| Intangible assets | 4,965,682 | 5,041,501 | -2 | % | ||
| NON CURRENT ASSETS | 14,120,068 | 16,888,370 | -16 | % | ||
| TOTAL ASSETS | $ | 42,762,182 | $ | 41,359,450 | 3 | % |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||
| CURRENT LIABILITIES | $ | 5,846,653 | $ | 5,405,106 | 8 | % |
| NON CURRENT LIABILITIES | 903,733 | 951,159 | -5 | % | ||
| Long term debt | – | – | 0 | % | ||
| Total Equity | 36,011,796 | 35,003,185 | 3 | % | ||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 42,762,182 | $ | 41,359,450 | 3 | % |
Article content
Article content
For further information please contact:
Article content
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: [email protected]
Phone: 905-206-0013
Web: www.biosyent.com
Article content
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Article content
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Article content
Article content
Article content
Article content
Article content
Article content
English (US)